We have located links that may give you full text access.
High incidence of orbital malignant lymphoma in Japanese patients.
American Journal of Ophthalmology 2004 November
PURPOSE: To review 244 cases of orbital tumors to determine pathologic findings in Japanese patients.
DESIGN: Observational case series.
METHODS: We studied the pathology and origin of tumors in the orbit in 244 consecutive Japanese patients with orbital tumors at our institution from 1981 through 2002 (age 0 to 90 years, mean, 48.7 years; 114 men, 130 women).
RESULTS: The most common tumors were lymphoproliferative diseases (n = 114, 42.5%), including malignant lymphoma (n = 59, 24.1%) and reactive lymphoid hyperplasia (n = 45, 18.4%), pleomorphic adenoma (n = 21, 8.6%), and cavernous hemangioma (n = 18, 7.4%).
CONCLUSION: The incidence of lymphoproliferative diseases, especially malignant lymphoma, was very high in Japanese patients.
DESIGN: Observational case series.
METHODS: We studied the pathology and origin of tumors in the orbit in 244 consecutive Japanese patients with orbital tumors at our institution from 1981 through 2002 (age 0 to 90 years, mean, 48.7 years; 114 men, 130 women).
RESULTS: The most common tumors were lymphoproliferative diseases (n = 114, 42.5%), including malignant lymphoma (n = 59, 24.1%) and reactive lymphoid hyperplasia (n = 45, 18.4%), pleomorphic adenoma (n = 21, 8.6%), and cavernous hemangioma (n = 18, 7.4%).
CONCLUSION: The incidence of lymphoproliferative diseases, especially malignant lymphoma, was very high in Japanese patients.
Full text links
Related Resources
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices 
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app